Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Halozyme Therapeutics, Inc.
  6. News
  7. Summary
    HALO   US40637H1095

HALOZYME THERAPEUTICS, INC.

(HALO)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
51.84 USD   -1.54%
02/06Halozyme Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
02/06Halozyme Appoints Barbara Duncan to its Board of Directors
PR
01/19Insider Sell: Halozyme Therapeutics
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Halozyme Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight

11/28/2022 | 02:20pm EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
HALOZYME THERAPEUTICS, INC. -1.54% 51.84 Delayed Quote.-8.89%
WELLS FARGO & COMPANY 0.21% 47.68 Delayed Quote.15.48%
All news about HALOZYME THERAPEUTICS, INC.
02/06Halozyme Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
02/06Halozyme Appoints Barbara Duncan to its Board of Directors
PR
01/19Insider Sell: Halozyme Therapeutics
MT
01/12Halozyme therapeutics inc. announces redemption of 1.25% convertible senior notes due 2..
AQ
01/11Sector Update: Health Care Stocks Recover Late
MT
01/11Sector Update: Health Care Stocks Drifting Wednesday Afternoon
MT
01/11Sector Update: Health Care
MT
01/11Halozyme Therapeutics Shares Fall Following 2023 Guidance
MT
01/11Halozyme therapeutics, inc. announces redemption of 1.25% convertible senior notes due ..
PR
01/10Transcript : Halozyme Therapeutics, Inc. Presents at 41st Annual J.P. Morgan ..
CI
More news
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 672 M - -
Net income 2022 183 M - -
Net Debt 2022 109 M - -
P/E ratio 2022 39,4x
Yield 2022 -
Capitalization 7 009 M 7 009 M -
EV / Sales 2022 10,6x
EV / Sales 2023 7,88x
Nbr of Employees 145
Free-Float 98,9%
Chart HALOZYME THERAPEUTICS, INC.
Duration : Period :
Halozyme Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 51,84 $
Average target price 56,22 $
Spread / Average Target 8,45%
EPS Revisions
Managers and Directors
Helen I. Torley President, Chief Executive Officer & Director
Nicole LaBrosse Executive Director & Controller
Connie L. Matsui Chairman
Michael J. LaBarre Chief Technical Officer & Senior Vice President
Steve Knowles Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HALOZYME THERAPEUTICS, INC.-8.89%7 009
REGENERON PHARMACEUTICALS, INC.8.54%83 397
VERTEX PHARMACEUTICALS4.24%78 258
WUXI APPTEC CO., LTD.12.89%39 435
BIONTECH SE-5.43%34 256
BEIGENE, LTD.11.48%25 531